Filing Flows › Health Care › Spero Therapeutics (SPRO)
Spero Therapeutics (SPRO) earnings and revenue breakdown
Latest: Q1 2026 · 10-Q filed May 13, 2026 · Spero Therapeutics (SPRO) Q1 2026 earnings results →
Q1 2026 Revenue down 96% year over year to $258K
Spero Therapeutics made $258K in Q1 2026 (-96% Y/Y). Operating margin n/m, net loss $7.2M. See where every dollar goes — costs, profit and cash — as a Sankey from the 10-Q filed May 13, 2026.
Drawing the Sankey…
Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF
What changed this quarter
Revenue was $258K in Q1 2026, down 96% year over year and down 99% from the previous quarter.
Operating costs exceeded revenue by $7.5M, an operating margin of -2921.7%. Total costs fell 62% while revenue fell 96%. The quarter ended with a net loss of $7.2M, after a profit of $31.5M the previous quarter.
Operating cash flow was $15.9M. Non-cash charges added back $1.1M of share-based compensation. Working capital and other items added $22.0M.
Quarterly history
| Quarter | Form | Filed | Revenue | Y/Y | Op. margin | Net earnings | Op. cash flow |
|---|---|---|---|---|---|---|---|
| Q1 2026 | 10-Q | May 13, 2026 | $258K | -96% | n/m | −$7.2M | $15.9M |
| Q4 2025 | 10-K | Mar 26, 2026 | $41.3M | +174% | 76.0% | $31.5M | −$8.4M |
| Q3 2025 | 10-Q | Nov 13, 2025 | $5.4M | -60% | -145.5% | −$7.4M | $17.4M |
| Q2 2025 | 10-Q | Aug 12, 2025 | $14.2M | +39% | -17.2% | −$1.7M | −$17.7M |
| Q1 2025 | 10-Q | May 13, 2025 | $5.9M | -37% | -250.8% | −$13.9M | −$4.0M |
| Q4 2024 | 10-K | Mar 27, 2025 | $15.0M | -80% | -144.4% | −$20.9M | −$23.4M |
Charts
Interactive views
The same charts as the app — open one to draw it.
💵Where each $1 goesinteractive
Loading the interactive chart…
🌏Named in Asian annual reportsinteractive
Loading the interactive chart…
🔄Rotation against the market and its industry (RRG)interactive
Loading the interactive chart…
🔍Earnings qualityinteractive
Loading the interactive chart…
⚖️Fair value by methodinteractive
Loading the interactive chart…
🔭Outlook & guidanceinteractive
Loading the interactive chart…
📈Investments: gains and what it boughtinteractive
Loading the interactive chart…
🏭Its industry’s money flow (input-output)interactive
Loading the interactive chart…
About Spero Therapeutics
Spero Therapeutics is a clinical-stage biopharmaceutical company focused on advancing next-generation medicines for patients with serious immune-mediated diseases. The company’s lead program, SP001, is a third-generation, Fc-silent anti-CD40L monoclonal antibody being advanced first in IgG4-related disease, with potential for development in additional immunological & inflammatory diseases. For more information, visit www.sperotx.com .
In its own words, from its 8-K, filed Aug 12, 2026.
Spero Therapeutics against its Pharmaceutical Preparations peers
The largest companies of the same SEC industry, each at its latest quarter. Revenue growth: -96% against the peers' median +7%.
| Company | Quarter | Revenue | Y/Y | Op. margin |
|---|---|---|---|---|
| SPRO Spero Therapeutics | Q1 2026 | $258K | -96% | n/m |
| JNJ Johnson & Johnson | Q3 2026 | $25.4B | +6% | 0.1% |
| LLY ELI Lilly | Q3 2026 | $24.4B | +39% | 34.5% |
| MRK Merck | Q3 2026 | $18.1B | +5% | 30.7% |
| ABBV AbbVie | Q3 2026 | $17.4B | +10% | 36.0% |
| PFE Pfizer | Q3 2026 | $16.6B | -0.4% | 20.4% |
| BMY Bristol Myers Squibb | Q3 2026 | $13.1B | +7% | 19.4% |
| ABT Abbott Laboratories | Q3 2026 | $13.0B | +14% | 10.4% |
| REGN Regeneron Pharmaceuticals | Q3 2026 | $5.1B | +36% | 40.0% |
Source: Spero Therapeutics 10-Q on SEC EDGAR · CIK 1701108 · Pharmaceutical Preparations
13F: who owns SPRO and who is buying
More on SPRO
History
Every quarter: Q1 2026 results · Q4 2025 results · Q3 2025 results · Q2 2025 results · Q1 2025 results · Q4 2024 results